Crispr Cash vs Common Stock Analysis
CRSP Stock | USD 47.88 1.59 3.43% |
Crispr Therapeutics financial indicator trend analysis is way more than just evaluating Crispr Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crispr Therapeutics is a good investment. Please check the relationship between Crispr Therapeutics Cash and its Common Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Cash vs Common Stock
Cash vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crispr Therapeutics Cash account and Common Stock. At this time, the significance of the direction appears to have strong relationship.
The correlation between Crispr Therapeutics' Cash and Common Stock is 0.76. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Common Stock in the same time period over historical financial statements of Crispr Therapeutics AG, assuming nothing else is changed. The correlation between historical values of Crispr Therapeutics' Cash and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Crispr Therapeutics AG are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Cash i.e., Crispr Therapeutics' Cash and Common Stock go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Cash
Cash refers to the most liquid asset of Crispr Therapeutics, which is listed under current asset account on Crispr Therapeutics AG balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Crispr Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Crispr Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Common Stock
Most indicators from Crispr Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. As of 11/25/2024, Tax Provision is likely to grow to about 3 M, while Selling General Administrative is likely to drop slightly above 62.4 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 539.6M | 563.3M | 463.5M | 279.2M | Cost Of Revenue | 101.2M | 110.3M | 130.3M | 113.9M |
Crispr Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Crispr Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Crispr Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1B | 1.8B | 2.8B | 2.2B | 2.2B | 1.3B | |
Other Current Liab | 41.7M | 49.6M | 79.0M | 61.9M | 34.9M | 30.6M | |
Total Current Liabilities | 57.1M | 94.3M | 119.9M | 121.1M | 108.8M | 63.5M | |
Total Stockholder Equity | 939.4M | 1.7B | 2.4B | 1.9B | 1.9B | 1.0B | |
Other Liab | 26.2M | 19.4M | 19.7M | 18.3M | 16.5M | 15.6M | |
Net Tangible Assets | 939.2M | 1.7B | 2.4B | 1.9B | 2.2B | 2.3B | |
Net Debt | (891.2M) | (1.1B) | (698.0M) | 32.1M | (150.8M) | (158.4M) | |
Retained Earnings | (224.7M) | (573.6M) | (195.9M) | (846.1M) | (999.7M) | (949.7M) | |
Accounts Payable | 5.9M | 9.1M | 14.8M | 27.4M | 38.1M | 40.1M | |
Cash | 943.8M | 1.2B | 923.0M | 211.9M | 389.5M | 528.6M | |
Non Current Assets Total | 79.2M | 111.3M | 334.4M | 390.0M | 321.5M | 337.6M | |
Non Currrent Assets Other | 6.1M | 18.1M | 22.2M | 16.3M | 13.6M | 9.7M | |
Other Assets | 6.1M | 18.1M | 22.2M | 16.3M | 18.7M | 19.7M | |
Cash And Short Term Investments | 943.8M | 1.7B | 2.4B | 1.8B | 1.7B | 1.1B | |
Net Receivables | 99K | 144K | 305K | 11.2M | 200M | 210M | |
Common Stock Total Equity | 1.8M | 2.3M | 2.4M | 2.4M | 2.8M | 1.6M | |
Common Stock Shares Outstanding | 56.9M | 65.9M | 80.4M | 77.7M | 79.2M | 57.1M | |
Liabilities And Stockholders Equity | 1.1B | 1.8B | 2.8B | 2.2B | 2.2B | 1.3B | |
Non Current Liabilities Total | 70.2M | 69.5M | 232.5M | 246.5M | 238.0M | 139.7M | |
Other Current Assets | 43.7M | 15.4M | 29.7M | 37.7M | 14.4M | 17.4M | |
Other Stockholder Equity | 1.2B | 2.2B | 2.6B | 2.7B | 2.9B | 3.0B | |
Total Liab | 127.3M | 163.7M | 352.4M | 367.6M | 346.8M | 203.2M | |
Total Current Assets | 987.5M | 1.7B | 2.4B | 1.9B | 1.9B | 1.1B | |
Accumulated Other Comprehensive Income | 7K | (83K) | (5.1M) | (15.6M) | 1.9M | 2.0M | |
Short Term Debt | 8.5M | 22.7M | 24.3M | 31.7M | 31.3M | 26.8M | |
Intangible Assets | 235K | 180K | 125K | 71K | 16K | 15.2K | |
Common Stock | 1.8M | 2.3M | 2.4M | 2.4M | 2.5M | 1.7M | |
Property Plant And Equipment Net | 72.8M | 93.0M | 312.0M | 320.6M | 305.9M | 321.2M | |
Capital Surpluse | 1.2B | 2.2B | 2.6B | 2.7B | 3.1B | 3.3B | |
Property Plant And Equipment Gross | 72.8M | 93.0M | 137.6M | 163.6M | 359.4M | 377.3M | |
Property Plant Equipment | 72.8M | 42.2M | 137.6M | 163.6M | 188.2M | 197.6M | |
Current Deferred Revenue | 960K | 2.3M | 1.0M | 12.3M | 4.1M | 3.9M | |
Retained Earnings Total Equity | (224.7M) | (573.6M) | (195.9M) | (846.1M) | (761.5M) | (723.4M) | |
Non Current Liabilities Other | 14.4M | 69.5M | 232.5M | 6.0M | 958K | 910.1K | |
Net Invested Capital | 939.4M | 1.7B | 2.4B | 1.9B | 1.9B | 1.5B |
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crispr Stock
0.53 | MTEM | Molecular Templates | PairCorr |
0.35 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.32 | TCHH | Trustcash Holdings | PairCorr |
0.31 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.